干扰素治疗肿瘤相关的信号通路及临床应用

国际肿瘤学杂志››2020,Vol. 47››Issue (6): 364-367.doi:10.3760/cma.j.cn371439-20191230-00037

干扰素治疗肿瘤相关的信号通路及临床应用

李钰祥, 王新文()

军事口腔医学国家重点实验室口腔疾病国家临床医学研究中心陕西省口腔疾病临床医学研究中心空军军医大学第三附属医院黏膜科,西安 710000

收稿日期:2019-12-30修回日期:2020-01-07出版日期:2020-06-08发布日期:2020-07-22
通讯作者:王新文 E-mail:landw211@163.com
基金资助:
国家自然科学基金(81371154);军事口腔医学国家重点实验室课题(2018ZB01)

Interferon-related signaling pathways and clinical application in tumor therapy

Li Yuxiang, Wang Xinwen()

State Key Laboratory of Military Stomatology & National Clinical Research Center for Oral Diseases & Shaanxi Clinical Research Center for Oral Diseases, Department of Oral Medicine, School of Stomatology, Fourth Military Medical University, Xi'an 710000, China

Received:2019-12-30Revised:2020-01-07Online:2020-06-08Published:2020-07-22
Contact:Wang Xinwen E-mail:landw211@163.com
Supported by:
National Natural Science Foundation of China(81371154);State Key Laboratory of Military Stomatology(2018ZB01)

摘要/Abstract

摘要：

Ⅰ、Ⅱ、Ⅲ型干扰素虽都具有抗肿瘤潜能,但作用机制和临床疗效有所不同。与干扰素治疗肿瘤相关的信号通路主要包括JAK-STAT、PI3K/AKT/mTOR、MAPK、NF-κB、c-Abl等。目前Ⅰ型干扰素临床应用最广,疗效最明确;Ⅱ型干扰素因存在严重的不良反应且可能在诱导癌变过程中发挥作用,对其是否可以用于抗肿瘤治疗存在较大争议;Ⅲ型干扰素虽在生物学功能上兼备了Ⅰ、Ⅱ型干扰素的优良特点,但其对抗肿瘤的药用价值还有待进一步评估。

关键词:干扰素类,肿瘤,信号通路,临床应用

Abstract:

Type Ⅰ, Ⅱ, Ⅲ interferons have anti-tumor potential, but the mechanism of action and clinical effect are different. Signaling pathways associated with interferon-treated tumors mainly include JAK-STAT, PI3K/AKT/mTOR, MAPK, NF-κB, c-Abl,etc. Type Ⅰ interferon has the widest clinical application and the most definite curative effect at present. Because of its serious adverse reaction and possible role in the process of cancer induction, type Ⅱ interferon has a great controversy on whether it can be used in anti-tumor therapy. The biological function of type Ⅲ interferon has good characteristics of type Ⅰ and Ⅱ interferon, but its anti-tumor medicinal value needs to be further evaluated.

Key words:Interferons,Neoplasms,Signal pathway,Clinical trial

李钰祥, 王新文. 干扰素治疗肿瘤相关的信号通路及临床应用[J]. 国际肿瘤学杂志, 2020, 47(6): 364-367.

Li Yuxiang, Wang Xinwen. Interferon-related signaling pathways and clinical application in tumor therapy[J]. Journal of International Oncology, 2020, 47(6): 364-367.

参考文献27

[1]	Rentiya ZS, Wells M, Bae J, et al. Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations[J]. Graefes Arch Clin Exp Ophthalmo, 2019,257(3):447-452. DOI: 10.1007/s00417-018-04209-7. doi:10.1007/s00417-018-04209-7
[2]	Sceneay J, Goreczny GJ, Wilson K, et al. Interferon signaling is diminished with age and is associated with Immune checkpoint blockade efficacy in triple-negative breast cance[J]. Cancer Discov, 2019,9(9):1208-1227. DOI: 10.1158/2159-8290.CD-18-1454. doi:10.1158/2159-8290.CD-18-1454pmid:31217296
[3]	Lasfar A, Gogas H, Zloza A, et al. IFN-λ cancer immunotherapy: new kid on the block[J]. Immunotherapy, 2016,8(8):877-888. DOI: 10.2217/imt-2015-0021. doi:10.2217/imt-2015-0021pmid:27381684
[4]	Mitchell S, Mercado EL, Adelaja A, et al. An NFκB activity calculator to delineate signaling crosstalk: type Ⅰ and Ⅱ interferons enhance NFκB via distinct mechanisms[J]. Front Immunol, 2019,10:1425. DOI: 10.3389/fimmu.2019.01425. doi:10.3389/fimmu.2019.01425pmid:31293585
[5]	Mojic M, Takeda K, Hayakawa Y. The dark side of IFN-γ: its role in promoting cancer immunoevasion[J]. Int J Mol Sci, 2017, 19(1). pii: E89. DOI: 10.3390/ijms19010089. pmid:29351251
[6]	Ni L, Lu J. Interferon gamma in cancer immunotherapy[J]. Cancer Med, 2018,7(9):4509-4516. DOI: 10.1002/cam4.1700. doi:10.1002/cam4.1700pmid:30039553
[7]	O'Brien TR, Young HA, Donnelly RP, et al. Meeting overview: interferon lambda-disease impact and therapeutic potential[J]. J Interferon Cytokine Res, 2019,39(10):586-591. DOI: 10.1089/jir.2019.0018. doi:10.1089/jir.2019.0018pmid:30998425
[8]	Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type Ⅰ and type Ⅲ interferons[J]. Immunity, 2019,50(4):907-923. DOI: 10.1016/j.immuni.2019.03.025. doi:10.1016/j.immuni.2019.03.025pmid:30995506
[9]	Zhao Q, Cheng W, Xi Y, et al. IFN-β regulates Th17 differentiation partly through the inhibition of osteopontin in experimental autoimmune encephalomyelitis[J]. Mol Immunol, 2018,93:20-30. DOI: 10.1016/j.molimm.2017.11.002. doi:10.1016/j.molimm.2017.11.002pmid:29127843
[10]	Bhat MY, Solanki HS, Advani J, et al. Comprehensive network map of interferon gamma signaling[J]. J Cell Commun Signal, 2018,12(4):745-751. DOI: 10.1007/s12079-018-0486-y. doi:10.1007/s12079-018-0486-ypmid:30191398
[11]	Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins[J]. J Interferon Cytokine Res, 2011,31(1):33-40. DOI: 10.1089/jir.2010.0100. doi:10.1089/jir.2010.0100pmid:21166594
[12]	Yeh YH, Hsiao HF, Yeh YC, et al. Inflammatory interferon activates HIF-1α-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway[J]. J Exp Clin Cancer Res, 2018,37(1):70. DOI: 10.1186/s13046-018-0730-6. doi:10.1186/s13046-018-0730-6pmid:29587825
[13]	Al-Attar R, Childers CL, Nguyen VC, et al. Differential protein phosphorylation is responsible for hypoxia-induced regulation of the Akt/mTOR pathway in naked mole rats[J]. Comp Biochem Physiol A Mol Integr Physiol, 2020,242:110653. DOI: 10.1016/j.cbpa.2020.110653. doi:10.1016/j.cbpa.2020.110653pmid:31926299
[14]	Ma RJ, Tan YQ, Zhou G, et al. Aberrant IGF1-PI3K/AKT/MTOR signaling pathway regulates the local immunity of oral lichen planus[J]. Immunobiology, 2019,224(3):455-461. DOI: 10.1016/j.imbio.2019.01.004. doi:10.1016/j.imbio.2019.01.004pmid:30773287
[15]	梁木林, 党红星, 鲁雪, 等. 抑制mTOR信号通路对幼鼠肺损伤时p-AKT1分子的影响及意义[J]. 中国病理生理杂志, 2019,35(3):506-514. DOI: 10.3969/j.issn.1000-4718.2019.03.021.
[16]	Wang H, Wang J, Shi X, et al. Genetically engineered bone marrow-derived mesenchymal stem cells co-expressing IFN-γ and IL-10 inhibit hepatocellular carcinoma by modulating MAPK pathway[J]. J BUON, 2017,22(6):1517-1524. pmid:29332347
[17]	Valledor AF, Sánchez-Tilló E, Arpa L, et al. Selective roles of MAPKs during the macrophage response to IFN-gamma[J]. J Immunol, 2008,180(7):4523-4529. DOI: 10.4049/jimmunol.180.7.4523. doi:10.4049/jimmunol.180.7.4523pmid:18354174
[18]	Truong AD, Hong Y, Hoang CT, et al. Chicken IL-26 regulates immune responses through the JAK/STAT and NF-κB signaling pathways[J]. Dev Comp Immunol, 2017,73:10-20. DOI: 10.1016/j.dci.2017.03.001. doi:10.1016/j.dci.2017.03.001pmid:28259699
[19]	Ning L, Huang X, Xu Y, et al. Boosting of hepatitis B virus-specific T cell responses after pegylated-interferon-alpha-2a therapy for hepatitis B e antigen-positive pediatric patients[J]. J Interferon Cytokine Res, 2019,39(12):740-751. DOI: 10.1089/jir.2019.0042. doi:10.1089/jir.2019.0042pmid:31329012
[20]	Suzuki T, Sakata K, Mizuno N, et al. Different involvement of the MAPK family in inflammatory regulation in human pulmonary microvascular endothelial cells stimulated with LPS and IFN-gamma[J]. Immunobiology, 2018,223(12):777-785. DOI: 10.1016/j.imbio.2018.08.003. doi:10.1016/j.imbio.2018.08.003pmid:30115376
[21]	Suarez-Kelly LP, Levine KM, Olencki TE, et al. A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma[J]. Cancer Immunol Immunother, 2019,68(4):619-629. DOI: 10.1007/s00262-019-02308-w. doi:10.1007/s00262-019-02308-wpmid:30725205
[22]	Lowenstein A, Fainboim H, Reyes A, et al. Autoimmune and non-autoimmune thyroid dysfunction in HCV infected and HCV-HIV co-infected patients before and after interferon alpha therapy: a prospective study[J]. Endocrinol Diabetes Nutr, 2019. pii: S2530-0164(19)30144-2. DOI: 10.1016/j.endinu.2019.04.012. doi:10.1016/j.endinu.2020.01.006pmid:32499203
[23]	Ding GQ, Yu YL, Shen ZJ, et al. Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells[J]. J Zhejiang Univ Sci B, 2012,13(5):335-341. DOI: 10.1631/jzus.B1100366. doi:10.1631/jzus.B1100366pmid:22556170
[24]	Liu Y, Liu G, Liu Q, et al. The cellular character of liquefaction degeneration in oral lichen planus and the role of interferon gamma[J]. J Oral Pathol Med, 2017,46(10):1015-1022. DOI: 10.1111/jop.12595. doi:10.1111/jop.12595pmid:28556960
[25]	Lv N, Gao Y, Guan H, et al. Inflammatory mediators, tumor necrosis factor-α and interferon-γ, induce EMT in human PTC cell lines[J]. Oncol Lett, 2015,10(4):2591-2597. DOI: 10.3892/ol.2015.3518. doi:10.3892/ol.2015.3518pmid:26622895
[26]	Gao D, Yu X, Zhang B, et al. Role of autophagy in inhibiting the proliferation of A549 cells by type Ⅲ interferon[J]. Cell Biol Int, 2019,43(6):605-612. DOI: 10.1002/cbin.11132. doi:10.1002/cbin.11132pmid:30958598
[27]	Choobin H, Bamdad T, Soleimanjahi H, et al. Antitumor effect of mIFN-lambda3 in C57BL/6 mice model for papilloma tumors[J]. Mol Biol (Mosk), 2015,49(5):777-784. DOI: 10.7868/S0026898415050067.